Human Peptide LL-37's DNA Binding Modulates Immune Cell Traps
Background
The human cathelicidin peptide LL-37 is a crucial component of the innate immune system, acting as a broad-spectrum antimicrobial peptide against bacteria, viruses, and fungi. Beyond its direct killing capabilities, LL-37 also plays a significant role in immunomodulation, influencing various immune cell functions. A key aspect of innate immunity involves neutrophil extracellular traps (NETs), web-like structures of decondensed chromatin and antimicrobial proteins released by neutrophils to ensnare and kill pathogens, but excessive NET formation is implicated in autoimmune diseases like lupus and psoriasis. Despite its known interactions with host components, the precise mechanisms by which LL-37 regulates its own activity and impacts NET formation, particularly through complexation with nucleic acids (DNA and RNA), remain poorly understood. This study specifically addresses how LL-37's binding patterns with nucleic acids influence its immunomodulatory functions, especially regarding NET release.
Results
The study revealed that LL-37 exhibits a strong and specific binding affinity for double-stranded DNA (dsDNA), with a dissociation constant (Kd) of approximately 250 nM, which was 3.5-fold higher than its affinity for single-stranded DNA (ssDNA) and 5-fold higher than for RNA. Complexation of LL-37 with dsDNA significantly altered its ability to induce neutrophil extracellular traps (NETs). When LL-37 was pre-incubated with dsDNA, the peptide's capacity to stimulate NET release from human neutrophils was markedly reduced, showing a 43% decrease in NET formation compared to LL-37 alone at the 5 µM concentration (p<0.001). This inhibitory effect was dose-dependent on the dsDNA concentration. > The most critical finding was that LL-37's interaction with host DNA acts as a crucial negative feedback loop, significantly modulating its pro-inflammatory potential and preventing excessive NETosis. Furthermore, the study found that specific modifications to the DNA structure, such as methylation, could subtly influence the binding kinetics and subsequent NET modulation, leading to a 15% less pronounced inhibitory effect on NETs (p<0.05) compared to unmodified dsDNA.
Why It Matters
This research provides fundamental insights into the complex regulatory mechanisms governing the human cathelicidin peptide LL-37, highlighting how its interaction with host nucleic acids can fine-tune its immune functions. Understanding this intricate interplay is crucial, as dysregulation of LL-37 and neutrophil extracellular traps (NETs) is implicated in various autoimmune and inflammatory diseases, including lupus, psoriasis, and rheumatoid arthritis. The discovery that DNA binding can attenuate LL-37-induced NETosis opens up novel therapeutic avenues. This mechanism could potentially be exploited to develop strategies for mitigating excessive inflammation and tissue damage in conditions characterized by overactive NET formation. Future research could explore small molecules or modified nucleic acids that mimic this regulatory interaction to therapeutically control LL-37 activity and NET-driven pathology in clinical settings. This work lays the groundwork for potential Phase I and II human trials targeting these pathways.